A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation

NCT00255281 Phase 2 COMPLETED

The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF

Details

Lead sponsor	AstraZeneca
Phase	Phase 2
Status	COMPLETED
Enrolment	160
Start date	2005-09
Completion	2006-05

Conditions

• Atrial Fibrillation

Interventions

• AZD7009, no generic name available

Primary outcomes

• The proportion of patients that have converted from AF within 90 minutes from start of infusion.

Countries

Denmark, Finland, Germany, Hungary, Netherlands, Norway, Poland, Sweden